

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 December 2018 (20.12.2018)



(10) International Publication Number
WO 2018/232202 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) *A61K 31/4985* (2006.01)
A61K 31/445 (2006.01) *C07D 211/46* (2006.01)

(21) International Application Number:

PCT/US2018/037687

(22) International Filing Date:

15 June 2018 (15.06.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/520,430	15 June 2017 (15.06.2017)	US
62/591,247	28 November 2017 (28.11.2017)	US
62/649,856	29 March 2018 (29.03.2018)	US
62/672,261	16 May 2018 (16.05.2018)	US


(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).

(72) Inventors; and

(71) Applicants: **BROWN, Jason W.** [US/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **HITCHCOCK, Stephen** [US/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **HOPKINS, Maria** [US/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **KIKUCHI, Shota** [JP/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **MON-ENSCHKEIN, Holger** [DE/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **REICHARD, Holly** [US/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **SCHLEICHER, Kristin** [US/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **SUN, Huikai** [CN/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **MACKLIN, Todd** [CA/US]; c/o Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US).

(54) Title: TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6

Figure 1



Pairwise repeated measures significant effect of treatment
F=4.91; p=0.0406. * p<0.05; **p<0.01; ***p<0.001 10mg/kg; # p<0.05 5mg/kg

(57) Abstract: Disclosed is a compound of Formula 1 as described in the specification and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.

[Continued on next page]

(74) **Agent: WARD, Donna T.** et al.; DT WARD, P.C., 142A Main Street, Groton, Massachusetts 01450 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))